Metraipolis › archive › dc_192596ab655f

Phase 2 dose-expansion trial of OBI-3424, a DNA-alkylating prodrug, in patients with advanced solid tumors expressing AKR1C3 — Europe PMC PMID:42390142

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42390142
DOI: 10.1093/oncolo/oyag254
License (as archived): solo-consultazione
Archived: 2026-10-18T14:16:53.579Z
SHA-256 of the archived text: 6b862cc5d64fff66bff703dd8a1d8b53b927b488b965116de2a46a1fc9bcc45d
Stable URL of this page: https://metraipolis.com/documento/dc_192596ab655f

How to cite

Phase 2 dose-expansion trial of OBI-3424, a DNA-alkylating prodrug, in patients with advanced solid tumors expressing AKR1C3 — Europe PMC PMID:42390142 — Europe PMC (en), https://europepmc.org/article/MED/42390142 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_192596ab655f (Metraipolis archive dc_192596ab655f, sha256 6b862cc5d64fff66bff703dd8a1d8b53b927b488b965116de2a46a1fc9bcc45d)

BibTeX

@misc{dc192596ab655f,
  title = {Phase 2 dose-expansion trial of OBI-3424, a DNA-alkylating prodrug, in patients with advanced solid tumors expressing AKR1C3 — Europe PMC PMID:42390142},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42390142},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_192596ab655f; sha256 6b862cc5d64fff66bff703dd8a1d8b53b927b488b965116de2a46a1fc9bcc45d},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42390142. Agents can read the archived copy with the MCP tool read_document.